EPNextS Group, a Japan-based provider of clinical trial solutions, announced on Tuesday that it has collaborated with Frontage Laboratories Inc, a US based full-service contract research organisation (CRO).
The collaboration is aimed at addressing the challenges of 'Drug Lag' and 'Drug Loss' in Japan. The companies say that Japan's pharmaceutical market faces significant hurdles related to the lag in the introduction of new drugs compared to other developed countries, often resulting in delays in patient access to life-saving medications. Additionally, stringent regulatory requirements and complex clinical trial procedures contribute to drug loss, where promising therapies fail to reach the market due to inefficiencies in the development process.
Both parties intend to leverage EPNextS' expertise in clinical trial solutions and Frontage's extensive experience in early-phase drug development and clinical research services, to overcome these challenges and drive positive change in the pharmaceutical landscape.
Tatsuma Nagaoka, of EPNextS representative director and president, said: "We are excited to join forces with Frontage to address the critical issues of drug lag and drug loss in Japan. Our collaboration with Frontage underscores our commitment to advancing clinical research and improving patient access to innovative therapies. By combining our strengths, we aim to streamline the drug development process and bring novel treatments to market more efficiently."
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma